Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it ...

The Department of Health and Human Services will aim to negotiate drug prices down to the lowest prices paid by peer nations, ...

The Trump administration just dropped a bomb on Big Pharma. In a bold new move, the U.S. Department of Health and Human ...

Tourmaline Bio is well-funded, with cash runway into 2H 2027, minimizing near-term dilution risk for investors. Click here to ...

Fintel reports that on May 14, 2025, Leerink Partners downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

The new data from PureTech come after the company reported successful results from the phase 2b Elevate study in December ...

UnitedHealth Group said 2025 revenue at Optum would be $10 billion less than previously estimated. Now the company is saying ...

Johnson & Johnson (NYSE:JNJ) stock and Halozyme (HALO) stock were downgraded at Leerink Partners on earlier than expected price controls for products. Read more here.

Pfizer will pay China’s 3SBio $1.25 billion upfront to gain access to a cancer therapy that could rival Akeso and Summit’s ...

On Tuesday, Leerink Partners adjusted its stance on Johnson & Johnson (NYSE:JNJ) stock, downgrading it from Outperform to Market Perform. The firm also lowered its price target to $153 from the ...

The FDA's full approval of Nuvaxovid triggered a $175 million milestone payment to Novavax from Sanofi, related to their ...